Autolus Therapeutics (AUTL) Cash from Financing Activities (2017 - 2025)
Autolus Therapeutics posted quarterly Cash from Financing Activities of -$1.8 million for Q4 2025, down 105.99% year-on-year from $30.0 million in Q4 2024, and down 1.3% on a QoQ basis from -$1.8 million in Q3 2025.
Autolus Therapeutics (AUTL) has 9 years of Cash from Financing Activities data on file, last reported at -$1.8 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 105.99% year-over-year to -$1.8 million; the trailing twelve-month figure through Dec 2025 stood at -$4.3 million (down 100.74% YoY), and the FY2025 full-year result was -$4.3 million, down 100.74% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$1.8 million, down from -$1.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $561.4 million in Q1 2024 and bottomed at -$2.1 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is $13500.0 (2023), against an average of $60.7 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities slumped 69000.0%; it then jumped 130365.22% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $147.4 million in 2021, then surged by 51.62% to $223.5 million in 2022, then tumbled by 99.99% to $23000.0 in 2023, then surged by 130365.22% to $30.0 million in 2024, then tumbled by 105.99% to -$1.8 million in 2025.
- The last three Cash from Financing Activities figures came in at -$1.8 million (Q4 2025), -$1.8 million (Q3 2025), and -$768000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.80 Mn |
| Dec 31, 2025 | -1.80 Mn |
| Sep 30, 2025 | -1.77 Mn |
| Sep 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | -768,000.00 |
| Jun 30, 2025 | -768,000.00 |
| Dec 31, 2024 | 30.01 Mn |
| Dec 31, 2024 | 30.01 Mn |
| Sep 30, 2024 | 185,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | -2.08 Mn |
| Mar 31, 2024 | 561.44 Mn |
| Mar 31, 2024 | 561.44 Mn |
| Dec 31, 2023 | 23,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | -219,000.00 |
| Jun 30, 2023 | -219,000.00 |
| Mar 31, 2023 | -691,000.00 |
| Mar 31, 2023 | -691,000.00 |
| Dec 31, 2022 | 223.51 Mn |
| Dec 31, 2022 | 223.51 Mn |
| Sep 30, 2022 | 102,000.00 |
| Sep 30, 2022 | 102,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | 147.42 Mn |
| Dec 31, 2021 | 147.42 Mn |
| Sep 30, 2021 | -230,000.00 |
| Sep 30, 2021 | -230,000.00 |
| Jun 30, 2021 | 13.55 Mn |
| Jun 30, 2021 | 13.55 Mn |
| Mar 31, 2021 | 123.32 Mn |
| Mar 31, 2021 | 123.32 Mn |
| Dec 31, 2020 | 392,000.00 |
| Dec 31, 2020 | 392,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Jun 30, 2020 | -297,000.00 |
| Jun 30, 2020 | -297,000.00 |
| Mar 31, 2020 | 74.31 Mn |
| Mar 31, 2020 | 74.31 Mn |
| Jun 30, 2019 | 109.41 Mn |
| Jun 30, 2019 | 109.41 Mn |
| Mar 31, 2019 | 4,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Jun 30, 2018 | 159.67 Mn |
| Jun 30, 2018 | 159.67 Mn |
| Dec 31, 2017 | 433,000.00 |
| Dec 31, 2017 | 433,000.00 |